HomeCompareVDRM vs JNJ

VDRM vs JNJ: Dividend Comparison 2026

VDRM yields 500000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VDRM wins by $4.663521010693878e+33M in total portfolio value
10 years
VDRM
VDRM
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full VDRM calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — VDRM vs JNJ

📍 VDRM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVDRMJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VDRM + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VDRM pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VDRM
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, VDRM beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VDRM + JNJ for your $10,000?

VDRM: 50%JNJ: 50%
100% JNJ50/50100% VDRM
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VDRM
No analyst data
Altman Z
-4.7
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VDRM buys
0
JNJ buys
0
No recent congressional trades found for VDRM or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVDRMJNJ
Forward yield500000.00%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$4.663521010693878e+33M$20.0K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$827.78
Total dividends collected$4.6634009849658873e+33M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VDRM vs JNJ ($10,000, DRIP)

YearVDRM PortfolioVDRM Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$50,010,700$50,000,000.00$10,676$355.77+$50.00MVDRM
2$233,748,371,262$233,694,859,813.08$11,407$389.39+$233748.36MVDRM
3$1,021,074,511,412,696$1,020,824,400,655,446.10$12,198$426.53+$1021074511.40MVDRM
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$13,056$467.62+$4168597328794.94MVDRM
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$13,987$513.12+$15905475114600664.00MVDRM
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$14,998$563.56+$56718938532531060736.00MVDRM
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$16,098$619.52+$1.8903180743562385e+23MVDRM
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$17,295$681.69+$5.8879981047651824e+26MVDRM
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$18,599$750.82+$1.7140642681147225e+30MVDRM
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.663521010693878e+33MVDRM

VDRM vs JNJ: Complete Analysis 2026

VDRMStock

ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.

Full VDRM Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this VDRM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VDRM vs SCHDVDRM vs JEPIVDRM vs OVDRM vs KOVDRM vs MAINVDRM vs ABBVVDRM vs MRKVDRM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.